Loading…
ImmuCell Corporation is projected to rise to $13.55 by 2027, a +24% move from its current price of $10.89. ICCC is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $10.55 | $10.90 | $11.25 | +0.06% |
| Jul 13 | $10.42 | $10.90 | $11.41 | +0.11% |
| Jul 14 | $10.32 | $10.91 | $11.54 | +0.17% |
| Jul 15 | $10.23 | $10.91 | $11.64 | +0.23% |
| Jul 16 | $10.16 | $10.92 | $11.74 | +0.29% |
| Jul 17 | $10.10 | $10.93 | $11.83 | +0.34% |
| Jul 18 | $10.04 | $10.93 | $11.91 | +0.40% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $10.04 | $10.93 | $11.91 | +0.40% |
| Week 2 | $9.73 | $10.98 | $12.38 | +0.80% |
| Week 3 | $9.51 | $11.02 | $12.78 | +1.21% |
| Week 4 | $9.33 | $11.07 | $13.12 | +1.62% |
| Week 5 | $9.18 | $11.11 | $13.44 | +2.02% |
| Week 6 | $9.05 | $11.15 | $13.75 | +2.43% |
| Week 7 | $8.94 | $11.20 | $14.03 | +2.84% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ImmuCell Corporation is an animal health company that develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis.
The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus.
It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation.
In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.
ImmuCell Corporation (ICCC) is currently priced at $11.46 per share with a market capitalization of $103.63M and a market rank of 4212.
The stock sits in a relatively modest capitalization tier, with a current price near $11.46 and a market cap around $103.63M. The forecast suggests a protracted upward trajectory from 2026 onward, with the average price rising from $11.46 in 2026 to $29.37 in 2030 and to $212.44 by 2050, delivering sizable upside across the horizon.
Forecasts show a steady ascent through mid-decade, with 2027 average price of $14.21, 2028 of $18.07, and 2029 of $22.76, culminating in a 2030 average of $29.37. The longer horizon envisions significant appreciation, with 2040 average $86.08 and 2050 average $212.44, accompanied by substantial ROIs.
Overall, the outlook is bullish over the multi-year horizon, though these figures are estimates and not guarantees.
A major floor 44.5% below — a decisive break under it would weaken the trend.
The nearest floor, 13.9% below — buyers have tended to step in here.
The nearest ceiling, 5.2% above — a clean break opens room to run.
A major ceiling 16.2% above — clearing it would confirm fresh momentum.
Key ICCC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ICCC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $10.68 | Buy | $10.79 | Buy |
| MA 10 | $10.44 | Buy | $10.52 | Buy |
| MA 20 | $10.05 | Buy | $10.22 | Buy |
| MA 50 | $9.62 | Buy | $9.53 | Buy |
| MA 100 | $8.22 | Buy | $8.63 | Buy |
| MA 200 | $7.13 | Buy | $7.65 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.13 | Neutral |
| Stoch RSI (14) | 32.07 | Neutral |
| CCI (20) | 129.33 | Buy |
| Williams %R (14) | -33.33 | Info |
| MACD (12,26,9) | 0.09 | Buy |
| ROC (12) | 10.33 | Buy |
| Bollinger %B (20,2) | 0.88 | Neutral |
| Stochastic %K (14) | 66.67 | Neutral |
| TRIX (15) | 0.38 | Buy |
| Awesome (5,34) | 0.66 | Buy |
| Ultimate (7,14,28) | 61.07 | Neutral |
| Momentum (10) | 1.00 | Buy |
| Aroon Osc (25) | 60.00 | Buy |
| Hull MA (9) | 11.06 | Sell |
| ADX (14) | 19.34 | Neutral |
| ATR (14) | 0.32 | Info |
The 30-day technical picture is bullish with a strong near-term tone.
RSI(14) sits at 70, signaling bullish momentum. The stock trades above both the 50-day and 200-day moving averages, with SMA50 at $9.57 and SMA200 at $7.11, respectively.
Support is noted at $9.38 and resistance at $11.46, framing a well-defined near-term range. The 30-day range spans from $9.32 to $14.08, and annualized volatility sits around 60%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.84 | $10.89 | $15.12 | 0% | Neutral | |
| $10.61 | $13.55 | $18.43 | +24% | Bullish | |
| $13.04 | $17.23 | $24.44 | +58% | Bullish | |
| $16.00 | $21.74 | $31.88 | +100% | Bullish | |
| $20.36 | $28.36 | $42.75 | +160% | Bullish | |
| $23.28 | $33.17 | $51.23 | +205% | Bullish | |
| $25.38 | $36.94 | $58.29 | +239% | Bullish | |
| $26.87 | $39.90 | $64.21 | +266% | Bullish | |
| $27.28 | $41.29 | $67.64 | +279% | Bullish | |
| $34.93 | $53.84 | $89.68 | +394% | Bullish | |
| $50.22 | $84.18 | $150.27 | +673% | Bullish | |
| $108.50 | $210.91 | $416.07 | +18.4x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $5.84 | $10.89 | $13.34 | +0.00% |
| August 2026 | $9.78 | $11.60 | $14.18 | +6.54% |
| September 2026 | $9.59 | $11.47 | $14.20 | -1.11% |
| October 2026 | $9.30 | $11.21 | $14.02 | -2.31% |
| November 2026 | $9.54 | $11.56 | $14.59 | +3.11% |
| December 2026 | $9.74 | $11.87 | $15.12 | +2.75% |
Click any year to see its month-by-month ICCC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ICCC to range from $5.84 to $15.12 through 2026. The $10.89 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The ICCC price prediction for 2027 points to an average of $13.55 (low $10.61, high $18.43) — a potential gain of +24% on today's $10.89. Momentum favours further upside here.
In 2028, ICCC is projected to trade between $13.04 and $24.44, averaging $17.23 — a potential gain of +58% from today's $10.89. That is up +27% on the projected 2027 average. Buyers look set to stay in control over this stretch.
ImmuCell Corporation's 2029 outlook centres on $21.74, within a $16.00 to $31.88 range. That is up +26% on the projected 2028 average. That marks a +100% change versus current levels. Momentum favours further upside here.
By 2030, ICCC could reach as high as $42.75, with a base case around $28.36 and support toward $20.36 — roughly +160% from $10.89. Buyers look set to stay in control over this stretch.
Expect ICCC to range from $23.28 to $51.23 through 2031. The $33.17 average target implies a +205% move from current prices. That is up +17% on the projected 2030 average. Momentum favours further upside here.
The ICCC price prediction for 2032 points to an average of $36.94 (low $25.38, high $58.29) — a potential gain of +239% on today's $10.89. Buyers look set to stay in control over this stretch.
In 2033, ICCC is projected to trade between $26.87 and $64.21, averaging $39.90 — a potential gain of +266% from today's $10.89. That is up +8% on the projected 2032 average. Momentum favours further upside here.
ImmuCell Corporation's 2034 outlook centres on $41.29, within a $27.28 to $67.64 range. That is up +3% on the projected 2033 average. That marks a +279% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, ICCC could reach as high as $89.68, with a base case around $53.84 and support toward $34.93 — roughly +394% from $10.89. Momentum favours further upside here.
Expect ICCC to range from $50.22 to $150.27 through 2040. The $84.18 average target implies a +673% move from current prices. That is up +56% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The ICCC price prediction for 2050 points to an average of $210.91 (low $108.50, high $416.07) — a potential gain of +18.4x on today's $10.89. Momentum favours further upside here.
Investing $1,000 in ICCC today (≈ 91.827365 ICCC) could be worth
$19,367.15
+$18,367.15 (+1837%) by 2050 · US Dollar
Based on the average projected ICCC price of $210.91 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ICCCwould be worth at today's price.
$1,000 invested in ICCC on Jul 10, 2025 (≈ 153.374234 ICCC) would be worth
$1,670.25
+$670.25 (+67.0%) today · 1.67× · US Dollar
Based on a ICCC entry price of $6.52 vs. today's $10.89.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $10.29 | $1,058.31 | +5.8% |
| 1 month ago | $9.67 | $1,126.16 | +12.6% |
| 3 months ago | $7.08 | $1,538.14 | +53.8% |
| 6 months ago | $6.67 | $1,632.68 | +63.3% |
| 1 year ago | $6.52 | $1,670.25 | +67.0% |
| All time (5.0y) ago | $9.77 | $1,114.64 | +11.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ICCC forecast.
Our base-case forecast reaches $22.00 around 2030.
Implied market cap at $22.00: $199.03M
The multi-year forecast shows a clear bullish trajectory across the coming years, with strong upside implied by higher average prices and sizable ROIs.
By 2030, the forecast calls for an average price of $29.37 with an ROI of 156.4%, and a bullish sentiment for that year. The outlook continues to strengthen into 2040, where the average price is projected at $86.08 with an ROI of 651.5%, followed by a dramatic rise to an average of $212.44 in 2050 and an ROI of 1754.6%.
These figures point to a long-run expansion if the underlying dynamics hold, but it is important to note that these are estimates, not guarantees, and carry inherent uncertainty and risk.
Across years from 2027 onward, sentiment is described as bullish in the forecast, reflecting an expectation of continued price appreciation relative to the current level.
Tap a question to reveal the answer.
Average price in 2030 is $29.37 with an ROI of 156.4% and bullish sentiment.
Forecasts show bullish sentiment from 2027 onward, with annual averages rising from $14.21 (2027) to $29.37 (2030) and continuing to $212.44 (2050); ROIs rise from 24% (2027) to 1754.6% (2050).
Yes. The 2035 forecast shows an average price of $55.51, indicating the asset could surpass $50 by 2035.
The 30-day range is $9.32 to $14.08, RSI(14) is 70, SMA50 is $9.57, SMA200 is $7.11, with near-term support at $9.38 and resistance at $11.46; volatility is around 60%.
Current price is $11.46 and market cap is $103.63M; the rank is 4212.
ImmuCell Corporation Community Discussion
0Share your ImmuCell Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.